Insys Therapeutics, Andrew Long
Insys Therapeutics is well-known for its product, Subsys, a sublingual spray of fentanyl, which has hit the headlines due to a court case determining whether former executives are guilty of having bribed doctors to prescribe the powerful pain killer. It was announced today that the founder of the company, John Kapoor, and four colleagues were convicted of the charges against them.
As part of the company’s efforts to reshape its leadership amidst such negative publicity, it announced that Saeed Motahari would step down as CEO and be replaced by CFO, Andrew Long.
Motahari had been in the position for two years, after joining the company from another company that experienced its own legal troubles, Purdue Pharma.
Long has worked at the company for a similar length of time and moves into the role from within the company, after holding the role of CFO previously.
Unlike Motahari, Long’s previous working record consists of companies that are not linked to the opioid crisis in North America – having previously worked at Abbot Laboratories, Cambrex, and Thermo Fisher Scientific.
Long worked in the latter position for nine years, before becoming SVP of global finance at Patheon, a subsidiary of Thermo Fisher.
Replacing Long as CFO at the company will be Andrece Housley, currently corporate controller. While an additional leadership change sees Venkat Goskonda become CSO of the company.
